HBSC... .26x.264 10 day adverage 219,343
nice uptick last week.. break out at .30 imo , I see 50.60 very soon... good bid support stock ticks up .3-.5 every few hundred K shares of trading...
Human BioSystems, Inc. (OTCBB: HBSC)
Human BioSystems, Inc. (OTCBB: HBSC) is a biomedical company that has developed and is now preparing to commercialize its proprietary technology to extend the shelf life of blood platelets, the congealing component of blood. The company is also commencing a comprehensive research program to increase the shelf life and quality of donor organs including hearts, kidneys, livers and lungs, and has recently filed two provisional patents covering its preservation solution and process.
BLOOD PLATELET PRESERVATION
Why is this technology important? Cancer patients who undergo chemotherapy treatment cause damage to the platelet structure of the blood and its ability to
produce platelets for a period of time. The result is a longer period of recovery from this treatment. HBS’s proprietary technology will have the ability to provide longer shelf life for platelets allowing doctors to have available a larger, and healthier platelet inventory to help these patients to recover
THE OUTLOOK
Working with two independent blood centers, the company simplified and improved its platelet storage technology and is now commencing human infusion studies. Pending scheduling and approval steps, HBS anticipates completion of tests within the next several months Upon successful conclusion of the pre-clinical pilot tests, the company will request a meeting with FDA to outline clinical trials involving at least two Independent blood centers. The company anticipates having such a meeting by the end of 2005 and initiating clinical trials
such a meeting by the end of 2005 and initiating clinical trials shortly thereafter. Human BioSystems plans to license both its platelet and organ preservation technology to one or more strategic alliance partners that have the capability to manufacture and distribute the company’s proprietary solution to blood centers worldwide. Initial revenue from licensing is expected in 2006. The company estimates a multi-billion dollar market demand for its platelet and organ preservation system coupled with the post-transplant technology, once fully developed and commercialized.
HBS is looking for additional products that are close to commercialization to add to its pipeline.
THE TECHNOLOGY
Human BioSystems’ proprietary preservation systems for initial products consist of non-toxic liquid solutions, proprietary protocols and solutions. These systems do not employ toxic preservatives or special cryogenic techniques or complex equipment. The platelet system is designed to utilize and complement standard platelet collection and processing activities. Collected platelets are processed using Human BioSystems’ proprietary preservation solution and intended to be packaged in FDA approved plastic storage bags. Instead of being stored in a rocking device at room temperature, as is current industry practice,
the storage bags are cooled according to HBS protocol. The platelets are cooled to four degrees C and placed into standard blood refrigeration units for storage. The Company intends to show through human infusion studies that this process exhibits improvements in viability and longevity of the blood platelets when compared to standard platelets stored at room temperature. The Company also intends to demonstrate that HBS stored platelets exhibit minimal bacteria growth during the storage period when compared to current standards of platelet storage. The company’s organ storage solution at refrigerated temperatures appears to be better than currently used solutions and is
uniquely adaptable to use in sub-zero storage up to minus 80 degrees centigrade and lower. If further tests confirm the subzero results and FDA approval is granted, this could optimize donor/recipient matching and provide long-term storage of organs versus hours of storage under current methods available. The company has applied for patents covering the technologies and the processes outlined above. The company believes its technologies are readily applicable for preserving blood platelets and donor organs.
MANAGEMENT TEAM
Harry Masuda, - CEO - Former president of high tech company Piiceon, Inc. and founder of HK Microwave. He successfully negotiated acquisitions for both companies.
David Winter, M.D., President – Previously President, GenPharm Intl., Sangstat, Human Organ Sciences and others. He was also the NASA Director of Life Sciences, where he directed all medical, biological, and biomedical –engineering for the U.S. space program. Dr. Winter led the development, registration and approval of cyclosporine and six other major components.
Paul Okimoto, Board Chairman, EVP and co-founder, Previously president of Sanhill Systems. Expertise with high tech products in biological and biomedical fields.
Luis Toledo, M.D., Ph.D., Chief Medical Officer. Internationally recognized authority on organ transplantation and preservation. Authored numerous books
.
DISCLAIMER
Certain statements contained herein are ``forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward looking statements include, but are not limited to, those discussed in filings made by the Company with the Securities and Exchange Commission.
My posts are not buy or sell recommendations. I may buy, sell,own, go long and short on stocks I post about.
DO YOUR DD!
